TG THERAPEUTICS, INC. — Director's Dealing 2024

Jan 9, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TG THERAPEUTICS, INC. (TGTX)
CIK: 0001001316
Period of Report: 2024-01-05

Reporting Person: WEISS MICHAEL S (CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-06	Common Stock	A	1001908	—	Acquired	13074929	Direct

Footnotes

F1: Reflects a grant of restricted shares, which will vest and become non-forfeitable based on the Company's total shareholder return relative to the Nasdaq Biotechnology Index over a one-year to five-year period, provided that the Reporting Person remains an employee, director and/or consultant of the Company through each vesting date.

F2: Includes shares of restricted Common Stock, which vest over various time periods.